CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
26.23
1.28%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.11
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Omnicell Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 26.57
Open* 26.63
1-Year Change* -55.35%
Day's Range* 26.16 - 26.63
52 wk Range 28.72-77.14
Average Volume (10 days) 411.52K
Average Volume (3 months) 13.28M
Market Cap 1.49B
P/E Ratio -100.00K
Shares Outstanding 45.47M
Revenue 1.19B
EPS -0.77
Dividend (Yield %) N/A
Beta 0.84
Next Earnings Date Feb 8, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 17, 2024 26.23 -0.31 -1.17% 26.54 26.76 26.09
Apr 16, 2024 26.57 0.18 0.68% 26.39 27.22 26.35
Apr 15, 2024 26.81 0.37 1.40% 26.44 27.26 26.44
Apr 12, 2024 27.14 0.08 0.30% 27.06 27.14 26.45
Apr 11, 2024 27.29 -0.23 -0.84% 27.52 27.62 27.11
Apr 10, 2024 27.38 0.23 0.85% 27.15 27.73 26.46
Apr 9, 2024 28.61 1.03 3.73% 27.58 28.94 27.07
Apr 8, 2024 27.87 0.36 1.31% 27.51 27.88 27.22
Apr 5, 2024 27.47 0.32 1.18% 27.15 27.75 27.14
Apr 4, 2024 27.56 0.00 0.00% 27.56 28.39 27.44
Apr 3, 2024 27.51 0.09 0.33% 27.42 27.90 27.16
Apr 2, 2024 27.69 -0.34 -1.21% 28.03 28.03 27.00
Apr 1, 2024 28.60 -0.62 -2.12% 29.22 29.22 28.27
Mar 28, 2024 29.18 1.25 4.48% 27.93 29.67 27.93
Mar 27, 2024 29.17 1.29 4.63% 27.88 29.17 27.88
Mar 26, 2024 27.85 -0.29 -1.03% 28.14 28.42 27.66
Mar 25, 2024 28.33 0.43 1.54% 27.90 28.38 27.88
Mar 22, 2024 27.90 -0.19 -0.68% 28.09 28.72 27.89
Mar 21, 2024 28.41 0.49 1.76% 27.92 28.87 27.87
Mar 20, 2024 27.90 0.72 2.65% 27.18 27.92 26.84

Omnicell Events

Time (UTC) Country Event
Thursday, May 2, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Omnicell Inc Earnings Call
Q1 2024 Omnicell Inc Earnings Call

Forecast

-

Previous

-

Time (UTC)

12:30

Country

US

Event

Q1 2024 Omnicell Inc Earnings Release
Q1 2024 Omnicell Inc Earnings Release

Forecast

-

Previous

-
Tuesday, May 21, 2024

Time (UTC)

16:00

Country

US

Event

Omnicell Inc Annual Shareholders Meeting
Omnicell Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, May 22, 2024

Time (UTC)

20:30

Country

US

Event

Omnicell Inc Annual Shareholders Meeting
Omnicell Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Tuesday, July 30, 2024

Time (UTC)

10:59

Country

US

Event

Q2 2024 Omnicell Inc Earnings Release
Q2 2024 Omnicell Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1295.95 1132.02 892.208 897.027 787.309
Revenue 1295.95 1132.02 892.208 897.027 787.309
Cost of Revenue, Total 698.942 576.976 476.352 460.115 414.979
Gross Profit 597.005 555.042 415.856 436.912 372.33
Total Operating Expense 1298.27 1042.51 856.682 818.675 742.917
Selling/General/Admin. Expenses, Total 475.171 387.904 303.924 289.916 263.095
Research & Development 101.354 75.611 66.445 68.644 64.843
Operating Income -2.323 89.507 35.526 78.352 44.392
Interest Income (Expense), Net Non-Operating -0.13 -23.5 -6.177 -4.419 -8.776
Net Income Before Taxes -2.453 66.007 29.349 73.933 35.616
Net Income After Taxes 5.648 77.849 32.194 61.338 37.729
Net Income Before Extra. Items 5.648 77.849 32.194 61.338 37.729
Total Extraordinary Items 0 0
Net Income 5.648 77.849 32.194 61.338 37.729
Income Available to Common Excl. Extra. Items 5.648 77.849 32.194 61.338 37.729
Income Available to Common Incl. Extra. Items 5.648 77.849 32.194 61.338 37.729
Diluted Net Income 5.648 77.849 32.194 61.338 37.729
Diluted Weighted Average Shares 45.891 47.943 43.743 42.943 40.559
Diluted EPS Excluding Extraordinary Items 0.12307 1.62378 0.73598 1.42836 0.93023
Diluted Normalized EPS 0.44606 1.79624 0.884 1.42836 0.99914
Unusual Expense (Income) 22.803 2.02 9.961
Dilution Adjustment 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 298.973 290.629 297.674 348.059 331.386
Revenue 298.973 290.629 297.674 348.059 331.386
Cost of Revenue, Total 164.292 165.456 168.503 188.52 173.294
Gross Profit 134.681 125.173 129.171 159.539 158.092
Total Operating Expense 291.225 313.592 336.031 329.594 318.901
Selling/General/Admin. Expenses, Total 103.082 120.429 123.382 114.381 119.252
Research & Development 23.13 22.393 26.664 24.899 26.355
Unusual Expense (Income) 0.721 5.314 17.482 1.794 0
Operating Income 7.748 -22.963 -38.357 18.465 12.485
Interest Income (Expense), Net Non-Operating 4.461 1.781 2.843 -1.148 -1.711
Net Income Before Taxes 12.209 -21.182 -35.514 17.317 10.774
Net Income After Taxes 3.451 -15 -28.408 16.774 9.069
Net Income Before Extra. Items 3.451 -15 -28.408 16.774 9.069
Net Income 3.451 -15 -28.408 16.774 9.069
Income Available to Common Excl. Extra. Items 3.451 -15 -28.408 16.774 9.069
Income Available to Common Incl. Extra. Items 3.451 -15 -28.408 16.774 9.069
Diluted Net Income 3.451 -15 -28.408 16.774 9.069
Diluted Weighted Average Shares 45.472 44.887 44.68 45.819 46.26
Diluted EPS Excluding Extraordinary Items 0.07589 -0.33417 -0.63581 0.36609 0.19604
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.0862 -0.25722 -0.38148 0.40402 0.19604
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 881.812 780.702 829.414 483.238 397.134
Cash and Short Term Investments 341.848 359.716 496.174 127.21 67.192
Cash
Cash & Equivalents 330.362 349.051 485.928 127.21 67.192
Total Receivables, Net 299.469 240.894 190.117 218.362 196.238
Accounts Receivable - Trade, Net 299.469 240.894 190.117 218.362 196.238
Total Inventory 147.549 119.924 96.298 108.011 100.868
Prepaid Expenses 28.772 29.155 26.122 14.478 20.7
Other Current Assets, Total 64.174 31.013 20.703 15.177 12.136
Total Assets 2210.76 2142.5 1824.5 1240.81 1081.24
Property/Plant/Equipment, Total - Net 132.013 119.69 114.187 110.376 51.5
Property/Plant/Equipment, Total - Gross 258.657 241.637 220.488 226.091 152.289
Accumulated Depreciation, Total -126.644 -121.947 -106.301 -115.715 -100.789
Goodwill, Net 734.274 738.9 499.309 336.539 335.887
Intangibles, Net 323.666 374.611 262.238 209.937 200.505
Long Term Investments 32.924 18.391 22.156 19.75 17.082
Other Long Term Assets, Total 91.325 92.118 79.995 68.71 62.653
Total Current Liabilities 428.446 876.158 276.423 236.996 204.58
Accounts Payable 63.389 71.513 40.309 46.38 38.038
Accrued Expenses 224.912 192.335 125.56 91.972 69.829
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 488.152 0
Other Current Liabilities, Total 140.145 124.158 110.554 98.644 96.713
Total Liabilities 1080.62 995.807 857.001 395.556 401.625
Total Long Term Debt 566.571 0 467.201 50 135.417
Long Term Debt 566.571 0 467.201 50 135.417
Deferred Income Tax 2.095 51.705 39.633 39.09 41.484
Other Liabilities, Total 83.509 67.944 73.744 69.47 20.144
Total Equity 1130.14 1146.69 967.503 845.254 679.617
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.055 0.054 0.053 0.051 0.05
Additional Paid-In Capital 1046.76 1024.58 920.359 780.931 678.041
Retained Earnings (Accumulated Deficit) 390.728 368.571 290.722 258.792 197.454
Treasury Stock - Common -290.319 -238.109 -238.109 -185.074 -185.074
Other Equity, Total -17.087 -8.407 -5.522 -9.446 -10.854
Total Liabilities & Shareholders’ Equity 2210.76 2142.5 1824.5 1240.81 1081.24
Total Common Shares Outstanding 44.747 44.179 42.783 42.132 40.335
Note Receivable - Long Term 14.744 18.084 17.205 12.26 16.481
Short Term Investments 11.486 10.665 10.246
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 913.751 881.361 934.969 881.812 849.132
Cash and Short Term Investments 473.525 444.971 351.466 341.848 278.988
Cash & Equivalents 446.84 399.464 340.413 330.362 266.402
Short Term Investments 26.685 45.507 11.053 11.486 12.586
Total Receivables, Net 272.584 273.899 322.073 299.469 354.098
Accounts Receivable - Trade, Net 272.584 273.899 322.073 299.469 354.098
Total Inventory 116.144 130.577 141.156 147.549 147.096
Prepaid Expenses 28.072 23.577 28.075 28.772 26.708
Other Current Assets, Total 23.426 8.337 92.199 64.174 42.242
Total Assets 2221.57 2193.87 2250.84 2210.76 2179.69
Property/Plant/Equipment, Total - Net 132.324 130.91 126.601 132.013 132.489
Property/Plant/Equipment, Total - Gross 270.283 269.462 258.735 258.657 255.308
Accumulated Depreciation, Total -137.959 -138.552 -132.134 -126.644 -122.819
Goodwill, Net 734.328 735.523 734.895 734.274 731.294
Intangibles, Net 288.733 299.832 311.803 323.666 336.19
Long Term Investments 41.631 35.039 32.744 32.924 33.807
Note Receivable - Long Term 13.159 15.132 13.491 14.744 13.815
Other Long Term Assets, Total 97.649 96.075 96.335 91.325 82.958
Total Current Liabilities 369.361 370.157 453.968 428.446 376.681
Accounts Payable 49.92 47.192 63.407 63.389 73.517
Accrued Expenses 169.723 174.479 225.961 224.912 167.698
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 149.718 148.486 164.6 140.145 135.466
Total Liabilities 1034.14 1030.31 1108.3 1080.62 1044.29
Total Long Term Debt 568.887 568.114 567.342 566.571 565.803
Long Term Debt 568.887 568.114 567.342 566.571 565.803
Deferred Income Tax 1.565 1.511 1.558 2.095 16.14
Other Liabilities, Total 94.326 90.525 85.429 83.509 85.666
Total Equity 1187.44 1163.56 1142.54 1130.14 1135.4
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.056 0.056 0.055 0.055 0.055
Additional Paid-In Capital 1110.1 1088.82 1072.69 1046.76 1030.67
Retained Earnings (Accumulated Deficit) 384.732 379.179 375.728 390.728 419.136
Treasury Stock - Common -290.319 -290.319 -290.319 -290.319 -290.319
Other Equity, Total -17.129 -14.176 -15.608 -17.087 -24.142
Total Liabilities & Shareholders’ Equity 2221.57 2193.87 2250.84 2210.76 2179.69
Total Common Shares Outstanding 45.463 45.205 45.069 44.747 44.646
Current Port. of LT Debt/Capital Leases 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 5.648 77.849 32.194 61.338 37.729
Cash From Operating Activities 77.781 231.809 185.87 145.008 103.966
Cash From Operating Activities 86.931 72.99 61.067 53.559 51.35
Deferred Taxes -37.316 -3.272 -6.546 -1.339 -5.705
Non-Cash Items 95.984 87.582 61.855 47.26 31.31
Cash Taxes Paid 19.005 -1.733 10.343 7.761 3.489
Cash Interest Paid 1.438 1.917 0.522 3.582 7.487
Changes in Working Capital -73.466 -3.34 37.3 -15.81 -10.718
Cash From Investing Activities -58.669 -412.498 -279.866 -61.664 -54.374
Capital Expenditures -60.74 -58.335 -54.866 -61.664 -54.374
Other Investing Cash Flow Items, Total 2.071 -354.163 -225 0 0
Cash From Financing Activities -20.953 47.363 456.269 -23.479 -13.597
Financing Cash Flow Items -8.925 -19.985 -5.296 -11.991 -6.775
Issuance (Retirement) of Stock, Net -12.028 67.348 52.525 78.512 70.178
Issuance (Retirement) of Debt, Net 0 0 409.04 -90 -77
Foreign Exchange Effects -0.944 -0.974 0.437 0.153 -1.227
Net Change in Cash -2.785 -134.3 362.71 60.018 34.768
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -15 5.648 34.056 17.282 8.213
Cash From Operating Activities 12.77 77.781 -4.372 -25.547 -15.996
Cash From Operating Activities 21.974 86.931 64.843 43.017 21.124
Deferred Taxes -7.77 -37.316 -17.061 -9.506 -4.858
Non-Cash Items 25.952 95.984 69.282 47.394 22.306
Changes in Working Capital -12.386 -73.466 -155.492 -123.734 -62.781
Cash From Investing Activities -13.64 -58.669 -41.417 -25.55 -18.733
Capital Expenditures -13.64 -60.74 -43.509 -27.642 -15.341
Cash From Financing Activities 3.862 -20.953 -24.515 -33.571 -32.119
Financing Cash Flow Items -8.252 -8.925 -11.844 -2.484 1.14
Issuance (Retirement) of Stock, Net 12.114 -12.028 -12.671 -31.087 -33.259
Issuance (Retirement) of Debt, Net 0 0
Foreign Exchange Effects 0.176 -0.944 -1.425 -2.123 -0.411
Net Change in Cash 3.168 -2.785 -71.729 -86.791 -67.259
Other Investing Cash Flow Items, Total 0 2.071 2.092 2.092 -3.392

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Omnicell Company profile

About Omnicell, Inc.

Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming the pharmacy care delivery model through automation designed to replace manual, error-prone processes, combined with a single, cloud-based platform and advanced services offerings. Its point-of-care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company's Omnicell Interface Software provides interface and integration between its medication-use products or its supply products and a healthcare facility’s in-house information management systems. Its Central Pharmacy IV Compounding Service offers a comprehensive service model inclusive of IV robotic technology, data analytic tools, and clinical support for insourced sterile compounding programs.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Omnicell, Inc. revenues increased 27% to $1.13B. Net income increased from $32.2M to $77.8M. Revenues reflect Connected devices, software licenses, and other segment increase of 32% to $739.1M, SaaS, subscription software, and technology-enabled services segment increase from $53.8M to $112.5M, United States segment increase of 28% to $1.02B, Rest of the World segment increase of 18% to $111.2M.

Equity composition

Common Stock $.001 Par, 12/10, 100M auth., 37,148,706 issd. 4,121,123 shs. in Treas. @$65.1M. Insiders own 2.25%. Initial Public Offering: 8/07/01, 6Mshares @ $7 by U.S. Bancorp Piper Jaffray. 7/01 1-for-1.6 stock split. *NOTE: 8/01, the Company changed it's name from Omnicell.com.

Industry: Medical Software & Technology Services

4220 North Freeway
FORT WORTH
TEXAS 76137
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

US100

17,583.50 Price
+0.460% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

61,977.95 Price
+1.850% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,376.70 Price
+0.630% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.40

ETH/USD

3,032.49 Price
+2.010% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading